Folusho Adeosun: Raising Fetal Hemoglobin as a Powerful Protective Shield in Sickle Cell Disease
Folusho Adeosun, Founder and CEO at Mo’sho Adeosun Health Initiative, shared a post on LinkedIn:
“Raising Fetal Hemoglobin.
Raising fetal hemoglobin is one of the most powerful protective shields a sickle cell warrior can have.
Yet many warriors living with SCD still do not know what fetal hemoglobin is, why it matters, or how life-changing it can be.
Fetal hemoglobin (HbF) is the type of hemoglobin we all had before birth.
Unlike sickle hemoglobin(HbS), it does not sickle.
It keeps red blood cells round, flexible, and able to move smoothly through blood vessels.
When fetal hemoglobin levels increase, something powerful happens. Pain crises can reduce, hospital visits will become less frequent and blood flow improves.
For many warriors, medications like hydroxyurea work by helping the body produce more fetal hemoglobin.
While nutrition cannot directly raise HbF like medication, good nutrition supports red blood cell production.
Important nutrients that help include:
- Folate (Vitamin B9) – supports RBC formation
- Vitamin B12
- Zinc
- Vitamin D
- Omega-3 fatty acids
These help optimize blood health but do not replace HbF-stimulating therapy.
This is why patient education matters.
A warrior who understands their blood is a warrior who knows the care their body deserves.
Because sometimes the difference between surviving and thriving with SCD begins with understanding what is flowing through your veins.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Mar 17, 2026, 15:28Aafreen Kotadiya: Why a Great Blood Bank Team is a Rare and Powerful Asset in Transfusion Medicine
-
Mar 17, 2026, 15:26Nathan Connell: $50 Million Gift to Advance Cell and Gene Therapy at Mass General Brigham
-
Mar 17, 2026, 15:10Peter Zdziarski: Standing Together for Ultra Rare Bleeding Disorders Awareness Day
-
Mar 17, 2026, 14:58Heghine Khachatryan: PFO, Cryptogenic Stroke, and Factor V Leiden – Closure or Lifelong Anticoagulation?
-
Mar 17, 2026, 14:56Mahesan Subramaniam: A Visual Guide to Heart Valve Disease
-
Mar 17, 2026, 14:55Daniel Victor Ortigoza: Apixaban Shows Lower Bleeding Risk than Rivaroxaban in Acute VTE
-
Mar 17, 2026, 14:52Kanishk Kumar: ATTR Amyloidosis Therapeutics Market Poised for a Pipeline Revolution
-
Mar 17, 2026, 14:39Giordano Botta: VA and Allelica Partner on Clinical Study of PRS and PGx in Cardiovascular Prevention
-
Mar 17, 2026, 14:34Rishi Wadhera: Financial Burden Among Working-Age Adults With Cardiovascular Disease